# IMPROVED BREAST CANCER PROGNOSIS BASED ON A HYBRID MARKER SELECTION APPROACH

L. Hedjazi, M.-V. Le Lann, T. Kempowsky-Hamon CNRS, LAAS, 7, avenue du Colonel Roche, F-31077 Toulouse, France Université de Toulouse, UPS, INSA, INP, ISAE, LAAS, F-31077 Toulouse, France

> F. Dalenc, G. Favre INSERM U563 and Institut Claudius Regaud, Toulouse, France

Keywords: Feature selection, Fuzzy logic, Mixed-Type Data, Breast cancer prognosis.

Abstract:

ct: Clinical factors, such as patient age and histo-pathological state, are still the basis of day-to-day decision for cancer management. However, with the high throughput technology, gene expression profiling and proteomic sequences have known recently a widespread use for cancer and other diseases management. We aim through this work to assess the importance of using both types of data to improve the breast cancer prognosis. Nevertheless, two challenges are faced for the integration of both types of information: high-dimensionality and heterogeneity of data. The first challenge is due to the presence of a large amount of irrelevant genes in microarray data whereas the second is related to the presence of mixed-type data (quantitative, qualitative and interval) in the clinical data. In this paper, an efficient fuzzy feature selection algorithm is used to alleviate simultaneously both challenges. The obtained results prove the effectiveness of the proposed approach.

# **1 INTRODUCTION**

Breast cancer is one of the most common causes of death among women in the world. In 2009, an estimation of 192,370 new cases of invasive breast cancer was diagnosed, as well as 62,280 additional cases of in situ breast cancer in the United States alone. Along with 40,170 women are expected to die from breast cancer and 1,910 cases of breast cancer are expected to occur among men (data from the American Cancer Society, 2009). Consequently, an accurate cancer diagnosis and prognosis is needed to help physicians take the necessary treatment decisions and thereby reduce its related expensive medical costs. In the past decade microarray analysis has had a great interest in cancer management (Golub et al., 1999; Ramaswamy et al., 2001; Van't Veer et al., 2002). This technology allowed a more accurate cancer management such as diagnosis (Ramaswamy et al., 2001), prognosis (Van't Veer et al., 2002), treatment response prediction (Straver et al., 2009). Meanwhile, the introduction of this

technology has brought with it also new challenges related to the high dimensionality of microarray data and the low signal-to-noise ratio. During the premicroarray era, cancer management was guided by the clinical and histo-pathological knowledge gained from many decades of cancer research. It has been established recently that the integration of both information may improve the cancer management (Sun et al., 2007; Gevaert et al., 2006). In (Sun, 2007), a feature selection method (I-Relief) was used to perform markers selection. However, the used method works under the assumption that all the data are of quantitative type and therefore an arbitrary transformation of symbolic data to quantitative one was performed to cope with data heterogeneity. This transformation can be a source of distortion and information loss as it introduces a distance which was not present in the original data. In (Gevaert et al., 2006), a Bayesian network was used to perform breast cancer prognosis. The obtained results show only that their approach performs similarly to the 70-gene signature established by Van't Veer and colleagues (Van't

Hedjazi L., Le Lann M., Kempowsky-Hamon T., Dalenc F. and Favre G..

In Proceedings of the International Conference on Bioinformatics Models, Methods and Algorithms (BIOINFORMATICS-2011), pages 159-164 ISBN: 978-989-8425-36-2

IMPROVED BREAST CANCER PROGNOSIS BASED ON A HYBRID MARKER SELECTION APPROACH. DOI: 10.5220/0003152301590164

Veer et al., 2002) and claim that a variable selection is implicitly performed based on their (in) dependency through the Markov Blanket concept. These results do not mean necessarily that the clinical data contains no additional information to the genetic data; it only tells us that their approach does not fit well. In the present work, we use our recently developed method, referred to as MEMBAS for (MEmbership Margine Based FeAture Selection) (Hedjazi et al., 2010a), to prove the usefulness of the integration of both types of data by handling both challenges simultaneously: high-dimensionality and heterogeneity of data. The first challenge is one of the characteristic of microarray data related to the curse of dimensionality (Golub et al., 1999). To deal with this problem, MEMBAS method selects a small feature subset such that the performance of a learning algorithm is optimized. The second challenge concerns the problem of processing simultaneously different types of data (qualitative, quantitative, interval ...) present almost in all daily produced clinical datasets (Age, Sex, Tumour size, Tumour grade...). MEMBAS method answers also to this problem by a simultaneous mapping of all types of data on a homogeneous space in order to process them identically in this new resulted space.

This paper is organized as follows: the second section explains the fuzzy feature selection approach based on feature *fuzzification* and the MEMBAS selection procedure. An application is given in section 3 to prove the usefulness of the adopted approach through the derivation of a hybrid signature for breast cancer prognosis.

## **2** FUZZY FEATURE SELECTION

During the past decades, feature selection has played a crucial role in order to improve the learning algorithms performance by selecting only the most features for the problem relevant under investigation. Here, we use the term feature to refer to a marker. Existing feature selection algorithms are traditionally characterized as wrappers and filters according to the criterion used to search the relevant features (Kohavi and John, 1997; Guyon and Elisseeff, 2003). Wrapper algorithms optimize the performance of a specified machine-learning algorithm to assess the usefulness of the selected feature subset; whereas filter algorithms use an independent evaluation function based generally on a measure of information content (entropy, t-test,...) (Kohavi and John, 1997; Guyon and Elisseeff, 2003). Filter algorithms are computationally more efficient but perform worse than wrapper algorithms (Kohavi and John, 1997; Guyon and Elisseeff, 2003). Thereby, with filter algorithms the features are evaluated individually without taking into account the correlation information and redundancy problems. Hence, this can deteriorate drastically the classifier performance (Kohavi and John, 1997). On the other hand, daily produced medical datasets may contain mixed feature-types (numerical, symbolic data) as well as large number of irrelevant features. This also poses a great challenge for the existing machine-learning algorithms. Up to now, most elassical feature selection algorithms are suitable for numerical features but their efficiency decreases significantly whenever a mixed-type dataset problem is encountered. The second problem is assessed in emergent fields such as bioinformatics, where datasets may hold a huge number of irrelevant features.



Figure 1: MEMBAS general principle.

We have recently proposed a new feature selection algorithm, referred to as MEMBAS (Hedjazi *et al.*, 2010a), which alleviates the previously mentioned problems. MEMBAS enables to process in the same way the three types of data (numerical, qualitative and interval) based on an appropriate and simultaneous mapping using fuzzy logic concepts (Figure 1.). To avoid the heuristic search during the feature selection procedure, MEMBAS optimizes an objective function using classical optimization techniques. The feature's importance is therefore evaluated within a membership margin framework. As we address a problem with two classes (Recurrence or No

Recurrence), only a description of MEMBAS for binary class problems is given in this paper.

Let  $D = [x_n, C_n]_{n=1}^{N} \in X \times C$  be the training dataset, where  $x_n = [x_{nl}, x_{n2}, ..., x_{nm}]$  is the *n*-th data sample containing *m* features, and  $C_n$  its corresponding class label. In the first step the features subset is fuzzified using the empirical data based on the appropriate learning process according to each feature type. The resulting fuzzy sets represent the feature memberships to the two existing classes. Then, when a new representation of data in a homogeneous space "membership space" is obtained, a single processing can be performed whatever the initial type of data.

### 2.1 Feature Fuzzification

The feature fuzzification can be performed according to each feature type as follows:

### 2.1.1 Quantitative Type Features

The quantitative feature value is first normalized into the interval [0,1] by using the formula:

$$x_i = \hat{x}_i - \hat{x}_{i\min} / \hat{x}_{i\max} - \hat{x}_{i\min}$$
(1)

Where  $\hat{x}_i$  is the measured value of the i<sup>th</sup> feature

and  $x_i$  is its normalized value,  $x_{imin}$  and  $x_{imax}$  are the bounds of the i<sup>th</sup> feature given by the context or imposed by the expert.

In the case of quantitative features, several membership functions proposed by (Aguado and Aguilar, 1999) can be used for  $\mu_k^i$ . In this work we use the centred binomial membership function (2):

$$\mu_{k}^{i} \Big[ x_{i} \Big| \rho_{k}^{i}, \varphi_{k}^{i} \Big] = \varphi_{k}^{i^{1-|x_{i}-\rho_{k}^{i}|}} \Big( 1 - \varphi_{k}^{i} \Big)^{|x_{i}-\rho_{k}^{i}|}$$
(2)

where  $\rho_k$  is the i<sup>th</sup> feature prototype for class  $C_k$ and parameter  $\varphi_k$  measures the proximity of the feature value to the class prototype so that :

 $\forall x_i \neq \rho_k^i : \mu_k^i \left[ \rho_k^i \middle| \rho_k^i, \varphi_k^i \right] \ge \mu_k^i \left[ x_i \middle| \rho_k^i, \varphi_k^i \right] \text{ and for}$   $\varphi_1 \le \varphi_2 \quad \forall x_i \neq \rho_k^i \quad , \text{ we have the ordered}$   $\text{memberships } \mu_k^i \left[ x_i \middle| \rho_k^i, \varphi_2 \right] \ge \mu_k^i \left[ x_i \middle| \rho_k^i, \varphi_1 \right].$ 

### 2.1.2 Interval Type Features

The membership function for interval type variables

is chosen as the similarity (Hedjazi *et al.*, 2010b) between the symbolic interval value of the  $i^{th}$  variable  $x_i$  and the interval  $\rho_k^i = \left[\rho_k^{i-}, \rho_k^{i+}\right]$  representing the class  $C_k$  as:

$$u_k^i(x_i) = S(x_i, \rho_k^i)$$
(3)

Given 2 intervals  $A = \begin{bmatrix} a^+, a^- \end{bmatrix}$  and  $B = \begin{bmatrix} b^+, b^- \end{bmatrix}$ , their *distance*  $\partial$  is defined as:

$$\partial \left[A,B\right] = \max\left[0,\left(\max\left\{a^{-},b^{-}\right\}-\min\left\{a^{+},b^{+}\right\}\right)\right]$$

The similarity measure between two intervals A and B is defined as:

$$S(A,B) = \frac{1}{2} \left( \frac{\varpi[A \cap B]}{\varpi[A \cup B]} + 1 - \frac{\partial[A,B]}{\varpi[U]} \right)$$
(4)

Where the measure  $\boldsymbol{\varpi}$  of an interval X is given by:

 $\varpi[X] = upper.bound(X) - lower.bound(X)$ Let consider that  $m_k$  individuals have been assigned to class  $C_k$ , this class will have as prototype a vector whose components are the intervals obtained by the mean bounds:

$$\rho_k^{i^-} = \frac{1}{m_k} \sum_{j=1}^{m_k} x_i^{(j)^-} \qquad \text{and} \qquad \rho_k^{i^+} = \frac{1}{m_k} \sum_{j=1}^{m_k} x_i^{(j)^+} \tag{5}$$

Where  $x_i^{j-}$  is the *i*<sup>th</sup> variable lower bound of the *j*<sup>th</sup> sample and  $x_i^{j+}$  is its upper bound. Consequently, the resulted class prototype for the *r* interval variables is given by the vector of intervals:

$$\rho_{k} = \left[\rho_{k}^{1}, \rho_{k}^{2}, ..., \rho_{k}^{r}\right]^{T}$$

$$(6)$$

For a better conditioning of magnitudes and processing time minimization, normalization within the interval [0,1] is proposed:

$$x_{i}^{-} = \frac{\hat{x}_{i}^{-} - \hat{x}_{i\min}^{-}}{\hat{x}_{i\max}^{+} - \hat{x}_{i\min}^{-}}, \quad x_{i}^{+} = \frac{\hat{x}_{i}^{+} - \hat{x}_{i\min}^{-}}{\hat{x}_{i\max}^{+} - \hat{x}_{i\min}^{-}}$$
(7)

where  $\mathbf{x}_i = [\mathbf{x}_i, \mathbf{x}_i^+]$  is the normalized value; consequently, the domain  $U^i$  of any interval variable  $x_i$  becomes the unit interval [0,1].

### 2.1.3 Qualitative Type Features

For qualitative variables, the possible values of the  $i^{th}$  variable form a set of modalities:

$$D_i = \left\{ Q_1^i, \dots Q_j^i, \dots Q_{Mi}^i \right\}$$
(8)

The membership function for a qualitative variable  $x_i$ is specified as:

$$\mu_k^i \left( \boldsymbol{\chi}_i \right) = \left( \Phi_{k1}^i \right)^{q_{i1}} * \dots * \left( \Phi_{kMi}^i \right)^{q_{iMi}} \tag{9}$$

Where  $\Phi_{ki}^{i}$  is the frequency of modality  $Q_{i}^{i}$  in the class  $C_k$  and  $q_j^i = \begin{cases} 1 & \text{if } x_i = Q_j^i \\ 0 & \text{if } x_i \neq Q_j^i \end{cases}$ . Therefore, the class

prototypes are  $\Omega_k^i = \left[ \Phi_{k1}^i, \dots, \Phi_{kj}^i, \dots, \Phi_{kMi}^i \right]$ represented by

#### **Homogeneous Space of Features** 2.2

It results from the previous step that, in the binary class problems, a sample  $x_n$  from dataset D can be associated to two Membership Degree Vectors (MDVs) of dimension *m* given as follows: ECHNOL

$$U_{nc_{k}} = \left[\mu_{k}^{1}(\mathbf{x}_{n1}), \ \mu_{k}^{2}(\mathbf{x}_{n2}), ..., \ \mu_{k}^{m}(\mathbf{x}_{nm})\right]^{T}; \ k = 1, 2.$$
(10)

Where  $\mu_k^i(x_{ni})$  (i.e.  $\mu_k^i(x_i = x_{ni})$ ), is the membership function of class  $C_k$  evaluated at the given value  $x_{ni}$ of the  $i^{th}$  feature for sample  $x_n$ .

It is worthwhile to recall that the resulted MDVs contain the membership values relative to all features whatever their initial type. This guaranties the mapping of different feature types from completely heterogeneous spaces into a common space which is the membership space (Figure 1). Once all features are simultaneously mapped into a common space, they can be henceforth processed similarly either for a classification or feature selection task. Our focus in this work is the feature selection task. A membership margin has been introduced in (Hedjazi et al., 2010a) to estimate the features importance in the membership space whatever their type and number. We assume that the  $n^{\text{th}}$  data sample  $x_n = \begin{bmatrix} x_n^1, x_n^2, \cdots, x_n^m \end{bmatrix}$  is labelled by class c. Let  $\tilde{c}$  be the alternative class. We define a membership margin for sample  $x_n$  by:

$$\beta_{n} = \psi(U_{nc}) - \psi(U_{n\tilde{c}})$$
(11)

where  $U_{nc}$  and  $U_{n\tilde{c}}$  are respectively the membership degree vectors of sample xn to classes C and  $\widetilde{C}$ ,  $\psi(.)$  is an aggregation function defined as  $\Psi(Y) = \sum Y_i$  computing the global contribution of a subset of features to each class. Note that a sample  $x_n$  is correctly classified if  $\beta_n > 0$ . The basic idea to calculate the fuzzy feature weight is to scale the feature memberships in the membership space such that the leave-one-out error is minimized:

$$\max_{\mathbf{w}_{f}} \sum_{n=1}^{N} \beta_{n}(\mathbf{w}_{f}) = \sum_{n=1}^{N} \sum_{i=1}^{m} w_{fi} \mu_{c}^{i}(x_{ni}) - \sum_{i=1}^{m} w_{fi} \mu_{c}^{i}(x_{ni}) \}$$
(12)

S.t  $||w_f||_2^2 = 1, w_f \ge 0$ 

Where  $\beta_n(w_f)$  is the margin of  $x_n$  computed with respect to w<sub>f</sub>. The first constraint is the normalized bound for the modulus of  $w_f$  so that the maximization ends up with non infinite values, whereas the second guarantees the nonnegative property of the obtained weight vector. The classical Lagrangian optimization approach was used to solve the above problem and the following closed-form solution was obtained: 

$$\mathbf{OG} = \mathbf{w}_{f}^{*} = \frac{\mathbf{s}^{+}}{||\mathbf{s}^{+}||} \mathbf{LICATIONS}$$
where  $\mathbf{s} = \sum_{n=1}^{N} \{\mathbf{U}_{nc} - \mathbf{U}_{n\widetilde{c}}\}$ 
(13)

With  $s^{+} = [\max(s_1, 0), ..., \max(s_m, 0)]^T$ .

Therefore, MEMBAS is considered as one of the first feature selection algorithms that enable processing similarly mixed feature-type data. In addition, the objective function optimized by MEMBAS approximates the leave-one-out cross validation error. Therefore, MEMBAS chooses only the features if they contribute to the overall performance. Hence, it addresses the issues of features correlation and redundancy. Moreover, MEMBAS avoids the heuristic combinatorial search by using classical optimization approaches to achieve an analytical solution. In (Hedjazi et al., 2010a) an extensive experimental study was performed on large number of datasets presenting both challenges (mixed-type and high-dimensional data) to demonstrate the effectiveness of the algorithm. The novelty of the present study is the application of this method to derive a hybrid signature integrating simultaneously genes expression and heterogeneous clinical data (quantitative, qualitative, interval). Moreover, an extension of MEMBAS method has been also proposed for multiclass problems (Hedjazi et al., 2010a). Subsequently, the effectiveness of MEMBAS method is illustrated on a real-world problem of crucial importance: marker selection for breast cancer prognosis. The main aim for

performing this study is to improve cancer prognosis based on the dimensionality reduction principle when the data are possibly of mixed types. As it was mentioned in the previous section, MEMBAS enables a simultaneous selection of mixed-feature types by avoiding any related numerical and heuristic search complexities.

## **3 EXPERIMENTS AND RESULTS**

### **3.1 Dataset and Experiment Setup**

The data set used in this study consists of 295 breast cancer patients, divided into 2 classes according to the appearance of distant subclinical metastases: 88 patients with and 207 patients without distant metastases (Van de Vijver et al., 2002). 29 patients with missing data have been removed. The microarray data set contained 24188 gene expression values. The clinical data contained 11 variables:

- Age (quantitative)
- Tumour grade (interval: [3,5]; [6,7]; [8,9])
- Tumour size = T (qualitative:  $\leq 2$ cm;  $\geq 2$ cm)
- Nodal status = N (qualitative : pN0; '1-3';  $\geq$ 4)
- Mastectomy (qualitative : Yes, No)
- Estrogen Receptor expression (qualitative: Yes, No)
- Chemotherapy (qualitative: Yes, No)
- Hormonotherapy (qualitative: Yes, No)
- St. Gallen European criteria (qualitative: Chemo, No Chemo)
- NIH –US criteria (qualitative: Chemo, No Chemo
- Risk NIH (qualitative: low, intermediate, high)

The complete data set (clinical and microarray data) was divided, similarly as in (Chang et al., 2005), into a training set (132 patients) to perform feature selection and learn classifier parameters, and a validation set (134 patients) to assess the performance of the algorithm on data not used for training. The classification task was performed by using the fuzzy classification algorithm LAMDA (Learning Algorithm of Multivariate Data Analysis) (Aguado and Aguilar-Martin, 1999). LAMDA is a fuzzy methodology of conceptual clustering and classification. It is based on finding the global membership degree of a sample to an existing class, considering all the contributions of each of its features. This contribution is called the marginal adequacy degree (MAD). The MADs are combined using "fuzzy mixed connectives" as aggregation operators in order to obtain the global adequacy degree (GAD) of an element to a class. We have chosen this classifier because it handles in a unified way the three types of data (quantitative, qualitative and interval) without the need of any transformation. More details on this fuzzy classification method can be found in (Hedjazi et al., 2010b) which did not address the feature selection problem. MEMBAS is used here to derive a hybrid prognostic marker without resorting to any data transformation. To demonstrate the predictive power of the hybrid prognostic signature derived from the genetic and clinical markers, its performance was compared with those of clinical markers and the well known Amsterdam 70-genes signature (Van't Veer, 2002). Then, another comparison with purely clinical indices (NIH, St Gallen) was also performed.

## 3.2 Results

TECHN

Table 1 shows the obtained comparative results between the hybrid markers approach and other approaches. It can be observed that the best prediction accuracy is obtained by the proposed approach which achieves more than 70%, whereas only 66% is achieved using the 70-genes Amsterdam signature (Van't Veer, 2002). It must be noticed here that MEMBAS chooses only 15 hybrid markers, among them three are mixed-type clinical markers (Number of positive lymph nodes "qualitative", Estrogen Receptor "qualitative" and Grade "interval"), added to them 12 genes. This fact was established in many previous studies (Deepa and Claudine, 2005), where it was noted that these three clinical features still to date are considered as important prognostic factors. Therefore, MEMBAS chooses meaningful markers and allows reducing significantly the number of needed markers to perform a prognosis (12 genes compared to the 70 genes of the Amsterdam signature).

Table 1: Comparatives results between hybrid, clinical and genetic signatures.

	TP	FP	FN	TN	Sens	Spec	Acc
Hybrid	13	12	28	81	0.32	0.87	94/134 (70.15%)
70-genes	25	29	16	64	0.61	0.69	89/134 (66.42%)
Clinical	23	37	18	56	0.56	0.60	79/134 (58.96%)

To further demonstrate the effectiveness of the proposed approach, we compare in Table 2 our results with the following clinical conventional prognostic factors: the St. Gallen's European consensus and the NIH index. The St. Gallen and the

NIH prognostics were taken from the clinical dataset as given by (Chang *et al.*, 2005).

Table 2: Comparative results between hybrid markers and pure clinical indices (NIH, St Gallen).

	TP	FP	FN	TN	Sens	Spec	Acc
Hybrid	13	12	28	81	0.32	0.87	94/134 (70.15%)
NIH	41	91	0	2	1	0.02	41/134 (32.09%)
St Gallen	38	85	3	8	0.93	0.09	46/134 (34.33%)

Both indices have a very high sensitivity, but an intolerable low specificity which would lead to give unnecessary adjuvant systematic treatment to many patients. Thus the obtained hybrid markers outperforms also the pure clinically indices.

## 4 CONCLUSIONS

In this paper a new approach to perform cancer prognosis is proposed based on a hybrid marker selection. We evaluated our approach on a public available breast cancer prognosis dataset. Patients included in this dataset are classified into two groups according to whether a distant subclinical metastasis was occurred or not. This dataset represents two challenges: high-dimensionality (microarray data) and mixed-type data (clinical data). To cope appropriately with this, a marker selection was performed based on a fuzzy feature selection approach which handles both challenges. It has been shown that the obtained hybrid markers, composed of clinical markers and genes, can improve the prediction accuracy and outperform both genetic based approaches (i.e. the well-known Amsterdam 70-genes signature) and pure clinical indices (St Gallen and NIH). Moreover, the proposed approach reduces significantly the number of markers needed to perform a cancer prognosis task.

Future work will be devoted to test this algorithm on other public available datasets and integrate other sources of information than clinical and microarray data.

## REFERENCES

Aguado J. C., and Aguilar-Martin J., 1999. A mixed qualitative-quantitative self-learning classification technique applied to diagnosis, *QR'99 The Thirteenth International Workshop on Qualitative Reasoning*. Chris Price, 124-128.

- Chang H. Y., Nuyten D. S. A., Sneddon J. B., Hastie T., Tibshirani R., *et al.*, 2005. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *PNAS* 2005, 102 (10): 3738-3743
- Deepa, S., Claudine I., 2005. Utilizing Prognostic and Predictive Factors in Breast Cancer. *Current Treatment Options in Oncology* 2005, 6:147-159. Current Science Inc
- Gevaert O., De Smet F., Timmerman D., Moreau Y., De Moor B., 2006. Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian network, *Bioinformatics* 22 (14), 184-190.
- Golub T., Slonim D., Tamayo P., Huard C., Gaasenbeek M., et al., 1999. Molecular Classification of Cancer Class Discovery and Class Prediction by Gene Expression Monitoring, Science 286 (5439), 531-537.
- Guyon I., Elisseeff A., 2003. An introduction to variable and feature selection, J. Mach. Learn. Res, 3, 1157-1182.
- Hedjazi L., Aguilar-Martin J., Le Lann M. V., and Kempowsky T., 2010a, Membership-Margin based Feature Selection for Mixed-Type and High-Dimensional Data, *Fuzzy Sets and Systems Journal.*, submitted for publication.
- Hedjazi, L., Kempowsky T., Le Lann M. V., Aguilar-Martin J., 2010b. Prognosis of breast cancer based on a fuzzy classification method. 3rd International Joint Conference on Biomedical Engineering Systems and Technologies (BIOSTEC 2010); 1st International Conference on Bioinformatics (BIOINFORMATICS 2010). Valence (Spain), 20-23 January 2010, pp.123-130.
- Kohavi R., and John G. H., 1997. Wrapper for feature subset selection, *Artificial Intelligence* 97, 273-324.
- Ramaswamy S., Tamayo P., Rifkin R., Mukherjee S., Yeang C., et al., 2001. MultiClass Cancer Diagnosis Using Tumor Gene Expression Signatures, Proc. Nat'l Acad. Sc. USA 98 (26), 15149-15154.
- Straver M. E., Glas A. M., Hannemann J., Wesseling J., van de Vijver M. J., et al.,2009. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer, *Breast Cancer Res. Treat.*, doi:10.1007/s10549-009-0333-
- Sun Y., 2007. Iterative RELIEF for Feature Weighting: Algorithms, Theories, and Applications, *IEEE TPAMI*, 2 (6), 1035-1051.
- Sun Y., Goodison S., Li J., Liu L., Farmerie W., 2007. Improved breast cancer prognosis through the combination of clinical and genetic markers. *Bioinformatics, Gene expression*. Oxford University Press 23 (1), 30-37.
- Van't Veer L.J., Dai H., van de Vijver M. J., et al., 2002. Gene expression profiling predicts clinical outcome of breast cancer, *Nature*, 415, pp. 530-536.
- Van de Vijver M. J., He Y. D., Van't Veer L. J., Dai H., Hart A., *et al.*, 2002. A Gene expression signature as a predictor of survival in breast cancer, N Engl J Med, 347 (25), pp. 1999-2009.